Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

Vista sencilla de ítem
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorMelo González, Felipe
dc.contributor.authorGutierrez Vera, Cristián
dc.contributor.authorSchultz, Bárbara M.
dc.contributor.authorBerríos Rojas, Roslye V.
dc.contributor.authorRivera Pérez, Daniela
dc.contributor.authorPiña Iturbe, Alejandro
dc.contributor.authorHoppe Elsholz, Guillermo
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorMoreno Tapia, Daniela
dc.contributor.authorRíos, Mariana
dc.contributor.authorPalacios, Pablo A.
dc.contributor.authorGarcia Betancourt, Richard
dc.contributor.authorSantibañez, Álvaro
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorMendez, Constanza
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorSilva, Pedro H.
dc.contributor.authorDiethelm Varela, Benjamín
dc.contributor.authorAstudillo, Patricio
dc.contributor.authorCalvo, Mario
dc.contributor.authorCárdenas, Antonio
dc.contributor.authorGonzález, Marcela
dc.contributor.authorGoldsack, Macarena
dc.contributor.authorGutiérrez, Valentina
dc.contributor.authorPotin, Marcela
dc.contributor.authorSchilling, Andrea
dc.contributor.authorTapia, Lorena I.
dc.contributor.authorTwele, Loreto
dc.contributor.authorVillena, Rodolfo
dc.contributor.authorGrifoni, Albar
dc.contributor.authorSette, Alessandro
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorFasce, Rodrigo A.
dc.contributor.authorFernández, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamírez, Eugenio
dc.contributor.authorGaete Argel, Aracelly
dc.contributor.authorAcevedo, Mónica L.
dc.contributor.authorValiente Echeverría, Fernando
dc.contributor.authorSoto Rifo, Ricardo
dc.contributor.authorRetamal Díaz, Angello
dc.contributor.authorMuñoz Jofré, Nathalia
dc.contributor.authorMeng, Xing
dc.contributor.authorXin, Qianqian
dc.contributor.authorAlarcón Bustamante, Eduardo
dc.contributor.authorGonzález Aramundiz, José V.
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorÁlvarez Figueroa, María Javiera
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorAbarca, Katia
dc.contributor.authorPerret, Cecilia
dc.contributor.authorCarreño, Leandro J.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2023-04-05T18:08:31Z
dc.date.available2023-04-05T18:08:31Z
dc.date.issued2022-12
dc.descriptionIndexación: Scopus.es
dc.description.abstractMultiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD41 T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD41 T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD41 T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials .gov under no. NCT04992260.) IMPORTANCE This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD41 T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron. Copyright © 2022 Soto et al.es
dc.description.urihttps://journals-asm-org.recursosbiblioteca.unab.cl/doi/10.1128/mbio.01311-22
dc.identifier.citationmBio, Volume 13, Issue 6December 2022es
dc.identifier.doi10.1128/mbio.01311-22
dc.identifier.issn2161-2129
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/48257
dc.language.isoenes
dc.publisherAmerican Society for Microbiologyes
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectCoronaVaces
dc.subjectCOVID-19es
dc.subjectImmunogenicityes
dc.subjectPediatrices
dc.subjectPhase 3 clinical triales
dc.subjectSafetyes
dc.subjectSARS-CoV-2es
dc.subjectVaccineses
dc.subjectVariants of concernes
dc.titleInactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Childrenes
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Soto_Inactivated_vaccine_induced_SARS-COV-2_variant.pdf
Tamaño:
2.37 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista